Rucaparib Camsylate Patent Expiration
Rucaparib Camsylate is Used for treating cancers associated with deleterious BRCA mutations, such as epithelial ovarian, fallopian tube, primary peritoneal cancer, and metastatic castration-resistant prostate cancer. It was first introduced by Pharmaand Gmbh
Rucaparib Camsylate Patents
Given below is the list of patents protecting Rucaparib Camsylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Rubraca | US10130636 | High dosage strength tablets of rucaparib | Aug 17, 2035 | Pharmaand |
| Rubraca | US9987285 | High dosage strength tablets of rucaparib | Aug 17, 2035 | Pharmaand |
| Rubraca | US8859562 | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer | Aug 04, 2031 | Pharmaand |
| Rubraca | US10278974 | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one | Feb 10, 2031 | Pharmaand |
| Rubraca | US8754072 | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one | Feb 10, 2031 | Pharmaand |
| Rubraca | US9045487 | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one | Feb 10, 2031 | Pharmaand |
| Rubraca | US9861638 | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one | Feb 10, 2031 | Pharmaand |
| Rubraca | US8071579 | DNA damage repair inhibitors for the treatment of cancer | Aug 12, 2027 | Pharmaand |
| Rubraca | US8143241 | DNA damage repair inhibitors for treatment of cancer | Aug 12, 2027 | Pharmaand |
| Rubraca | US7351701 | Therapeutic compounds |
Jul 23, 2024
(Expired) | Pharmaand |
| Rubraca | US7531530 | Therapeutic compounds |
Jul 23, 2024
(Expired) | Pharmaand |
| Rubraca | US6495541 | Tricyclic inhibitors of poly(ADP-ribose) polymerases |
Nov 22, 2023
(Expired) | Pharmaand |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Rucaparib Camsylate's patents.
Latest Legal Activities on Rucaparib Camsylate's Patents
Given below is the list recent legal activities going on the following patents of Rucaparib Camsylate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 Nov, 2022 | US9045487 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Oct, 2022 | US10278974 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 04 May, 2022 | US10130636 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 01 Dec, 2021 | US8754072 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Nov, 2021 | US9987285 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 23 Jun, 2021 | US9861638 |
| Change in Power of Attorney (May Include Associate POA) Critical | 05 Mar, 2021 | US10130636 |
| Correspondence Address Change Critical | 04 Mar, 2021 | US9987285 |
| Correspondence Address Change Critical | 04 Mar, 2021 | US10130636 |
| Change in Power of Attorney (May Include Associate POA) Critical | 04 Mar, 2021 | US9987285 |
Rucaparib Camsylate's Family Patents
